Dr. West on FDA Approval of Lorlatinib in ALK+ NSCLC

H. Jack West, MD
Published: Friday, Nov 02, 2018



H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of lorlatinib for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).
SELECTED
LANGUAGE


H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of lorlatinib for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x